M Eric Hyndman
Overview
Explore the profile of M Eric Hyndman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hyndman M, Paproski R, Kinnaird A, Fairey A, Marks L, Pavlovich C, et al.
NPJ Digit Med
. 2024 Jun;
7(1):163.
PMID: 38902526
The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment...
2.
Nelson G, Wang X, Nelson A, Faris P, Lagendyk L, Wasylak T, et al.
JAMA Netw Open
. 2021 Aug;
4(8):e2119769.
PMID: 34357394
Importance: Engaging multidisciplinary care teams in surgical practice is important for the improvement of surgical outcomes. Objective: To evaluate the association of multiple Enhanced Recovery After Surgery (ERAS) pathways with...
3.
Falegan O, Jarvi K, Vogel H, Hyndman M
Prostate
. 2021 Jun;
81(11):713-720.
PMID: 34097313
Background: Prostate cancer (PCa) is a metabolic disease. Most men are diagnosed with low grade indolent disease and differentiating these men from those who have life threatening cancer is a...
4.
Steinberg R, Packiam V, Thomas L, Brooks N, Vitale A, Mott S, et al.
Urol Oncol
. 2021 Jun;
40(1):9.e1-9.e7.
PMID: 34092482
Introduction: Repeat BCG induction remains an option for select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have...
5.
Fu Z, Rais Y, Bismar T, Hyndman M, Le X, Drabovich A
Mol Cell Proteomics
. 2021 Mar;
20:100075.
PMID: 33771697
TMPRSS2-ERG gene fusion, a molecular alteration found in nearly half of primary prostate cancer cases, has been intensively characterized at the transcript level. However limited studies have explored the molecular...
6.
Bracey N, Platnich J, Lau A, Chung H, Hyndman M, MacDonald J, et al.
Life Sci Alliance
. 2020 Dec;
4(3).
PMID: 33376129
The pryin domain (PYD) domain is involved in protein interactions that lead to assembly of immune-sensing complexes such as inflammasomes. The repertoire of PYD-containing genes expressed by a cell type...
7.
Arias M, Haney E, Hilchie A, Corcoran J, Hyndman M, Hancock R, et al.
Biochim Biophys Acta Biomembr
. 2020 Mar;
1862(8):183228.
PMID: 32126228
Antimicrobial peptides (AMPs) constitute a diverse family of peptides with the ability to protect their host against microbial infections. In addition to their ability to kill microorganisms, several AMPs also...
8.
Steinberg R, Thomas L, Brooks N, Mott S, Vitale A, Crump T, et al.
J Urol
. 2019 Dec;
203(5):902-909.
PMID: 31821066
Purpose: Rescue intravesical therapies for patients with bacillus Calmette-Guérin failure nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel therapy has shown safety...
9.
Grivas P, Bismar T, Alva A, Huang H, Liu Y, Seiler R, et al.
Urol Oncol
. 2019 Dec;
38(4):262-268.
PMID: 31812633
Purpose: Neuroendocrine (NE)-like carcinoma is a newly recognized molecular subtype of conventional urothelial carcinoma of the bladder with transcriptomic profiles and clinical outcomes highly similar to histological NE carcinoma. The...
10.
Falegan O, Egloff S, Zijlstra A, Hyndman M, Vogel H
Metabolites
. 2019 Jul;
9(8).
PMID: 31344778
Renal cell carcinoma (RCC) is a heterogeneous malignancy which often develops and progresses asymptomatically. Benign oncocytomas are morphologically similar to malignant chromophobe RCC and distinguishing between these two forms on...